*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach - as a primary procedure code | 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach - as a primary or secondary procedure code | |
|---|---|---|
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | 39,216 | 58,585 |
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | 27,779 | 44,597 |
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total Medicare Hospitalizations after Exclusion | ||
| Avg. LOS | ||
| Readmission Rate (%) | ||
| Unplanned Readmission Rate (%) | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,065 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 14,205 | ||||
| DRG Share of Total Hospitalizations | 0.14 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 51.14 | ||||
| Avg LOS at DRG | 4.03 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 3.79 | ||||
| Readmission Rate at DRG | 66.75 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 66.27 | ||||
| Unplanned Readmission Rate at DRG | 10.94 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 10.71 | ||||
| Total Medicare payments at DRG | $438,494,977 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $134,229,108 | ||||
| Total Medicare payment per Day at DRG | $2,416 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $2,491 | ||||
| Total Medicare payment per Hospitalization at DRG | $9,730 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $9,449 | ||||
| Total Medicare Charges at DRG | $2,145,591,374 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $613,400,983 | ||||
| Avg Charges at DRG | $47,611 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $43,182 | ||||
| Mortality Rate at DRG | 0.08 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 0.08 | ||||
| SNF Discharge Rate at DRG | 4.35 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 4.58 | ||||
| Home Discharge Rate at DRG | 81.76 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 81.37 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 838: CHEMOTHERPY WITH ACUTE LEUKEMIA AS SDX WITH COMPLICATION OR COMORBIDITY (CC) OR HIGH DOSE CHEMOTHERAPY AGENT | DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | DRG 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 834: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 3,903 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 749 | ||||
| DRG Share of Total Hospitalizations | 0.01 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 2.7 | ||||
| Avg LOS at DRG | 7.61 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 6.6 | ||||
| Readmission Rate at DRG | 59.41 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 61.29 | ||||
| Unplanned Readmission Rate at DRG | 21.51 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 24.52 | ||||
| Total Medicare payments at DRG | $84,826,538 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $15,427,225 | ||||
| Total Medicare payment per Day at DRG | $2,856 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $3,120 | ||||
| Total Medicare payment per Hospitalization at DRG | $21,734 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $20,597 | ||||
| Total Medicare Charges at DRG | $328,471,815 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $46,423,012 | ||||
| Avg Charges at DRG | $84,159 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $61,980 | ||||
| Mortality Rate at DRG | NA | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | NA | ||||
| SNF Discharge Rate at DRG | 1.64 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | NA | ||||
| Home Discharge Rate at DRG | 76.53 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 76.64 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 181: RESPIRATORY NEOPLASMS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 842: LYMPHOMA AND NON-ACUTE LEUKEMIA WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 375: DIGESTIVE MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 436: MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 37,484 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 241 | ||||
| DRG Share of Total Hospitalizations | 0.11 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 0.87 | ||||
| Avg LOS at DRG | 4.49 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 5.97 | ||||
| Readmission Rate at DRG | 27.89 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 40.85 | ||||
| Unplanned Readmission Rate at DRG | 21.07 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 29.36 | ||||
| Total Medicare payments at DRG | $287,773,529 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $2,043,337 | ||||
| Total Medicare payment per Day at DRG | $1,709 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $1,420 | ||||
| Total Medicare payment per Hospitalization at DRG | $7,677 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $8,479 | ||||
| Total Medicare Charges at DRG | $1,483,578,942 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $13,586,904 | ||||
| Avg Charges at DRG | $39,579 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $56,377 | ||||
| Mortality Rate at DRG | 4.3 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | NA | ||||
| SNF Discharge Rate at DRG | 10.7 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 14.11 | ||||
| Home Discharge Rate at DRG | 44.82 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 48.96 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 829: MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 948: SIGNS AND SYMPTOMS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 809: MAJOR HEMATOLOGICAL AND IMMUNOLOGICAL DIAGNOSES EXCEPT SICKLE CELL CRISIS AND COAGULATION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 054: NERVOUS SYSTEM NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 5,149 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 131 | ||||
| DRG Share of Total Hospitalizations | 0.02 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 0.47 | ||||
| Avg LOS at DRG | 10.0 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 15.73 | ||||
| Readmission Rate at DRG | 32.03 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 58.93 | ||||
| Unplanned Readmission Rate at DRG | 16.46 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 23.21 | ||||
| Total Medicare payments at DRG | $138,052,599 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $4,913,806 | ||||
| Total Medicare payment per Day at DRG | $2,682 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $2,384 | ||||
| Total Medicare payment per Hospitalization at DRG | $26,812 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $37,510 | ||||
| Total Medicare Charges at DRG | $653,072,869 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $27,451,794 | ||||
| Avg Charges at DRG | $126,835 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $209,556 | ||||
| Mortality Rate at DRG | 5.59 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 12.21 | ||||
| SNF Discharge Rate at DRG | 12.02 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 15.27 | ||||
| Home Discharge Rate at DRG | 49.37 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 45.04 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 799 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 1275 YORK AVE | NEW YORK | NY | 10065 | 786 |
| NEWYORK PRESBYTERIAN - WEILL CORNELL MEDICAL CENTER | 525 E 68TH ST | NEW YORK | NY | 10021 | 505 |
| MASSACHUSETTS GENERAL HOSPITAL | 55 FRUIT ST | BOSTON | MA | 02114 | |
| MAYO CLINIC HOSPITAL - SAINT MARYS CAMPUS | 1216 2ND ST SW | ROCHESTER | MN | 55902 | |
| HACKENSACK UNIVERSITY MEDICAL CENTER | 30 PROSPECT AVE | HACKENSACK | NJ | 07601 | |
| THE JOHNS HOPKINS HOSPITAL | 600 N WOLFE ST | BALTIMORE | MD | 21287 | |
| BARNES JEWISH HOSPITAL | 1 BARNES-JEWISH HOSPITAL PLZ | SAINT LOUIS | MO | 63110 | |
| BRIGHAM AND WOMEN'S HOSPITAL | 75 FRANCIS ST | BOSTON | MA | 02115 | |
| HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA | 3400 SPRUCE ST | PHILADELPHIA | PA | 19104 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 | 109 |
| Dr. TATYANA A FELDMAN | 92 2ND ST | HACKENSACK | NJ | 07601 | 78 |
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 73 |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | |
| Dr. CHRISTIAN GROMMES | 1275 YORK AVE | NEW YORK | NY | 10065 | |
| Dr. SUDHA KAVURU | 40 BEY LEA RD | TOMS RIVER | NJ | 08753 | |
| Dr. TAMARA LEA MUSGRAVE | 172 S MAYO TRL | PIKEVILLE | KY | 41501 | |
| Dr. MICHAEL PATTEN CARROLL | 1020 29TH ST | SACRAMENTO | CA | 95816 | |
| Dr. VASANTI J DAMLE | 2 MARINE VIEW PLZ | HOBOKEN | NJ | 07030 | |
| Dr. JOHN NATHAN ALLAN | 520 E 70TH ST | NEW YORK | NY | 10021 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 | 117 |
| Dr. TATYANA A FELDMAN | 92 2ND ST | HACKENSACK | NJ | 07601 | 80 |
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 77 |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | |
| Dr. CHRISTIAN GROMMES | 1275 YORK AVE | NEW YORK | NY | 10065 | |
| Dr. SUDHA KAVURU | 40 BEY LEA RD | TOMS RIVER | NJ | 08753 | |
| Dr. TAMARA LEA MUSGRAVE | 172 S MAYO TRL | PIKEVILLE | KY | 41501 | |
| Dr. MICHAEL PATTEN CARROLL | 1020 29TH ST | SACRAMENTO | CA | 95816 | |
| Dr. RAUNAQ DUSHYANTKUMAR BHATT | 55 MADISON AVENUE | MORRISTOWN | NJ | 07960 | |
| Dr. JOHN NATHAN ALLAN | 520 E 70TH ST | NEW YORK | NY | 10021 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | DRG 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 45,065 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 15,700 | ||||
| DRG Share of Total Hospitalizations | 0.14 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 35.2 | ||||
| Avg LOS at DRG | 4.03 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 3.89 | ||||
| Readmission Rate at DRG | 66.75 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 66.45 | ||||
| Unplanned Readmission Rate at DRG | 10.94 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 10.92 | ||||
| Total Medicare payments at DRG | $438,494,977 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $150,883,804 | ||||
| Total Medicare payment per Day at DRG | $2,416 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $2,471 | ||||
| Total Medicare payment per Hospitalization at DRG | $9,730 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $9,610 | ||||
| Total Medicare Charges at DRG | $2,145,591,374 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $708,840,086 | ||||
| Avg Charges at DRG | $47,611 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $45,149 | ||||
| Mortality Rate at DRG | 0.08 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 0.08 | ||||
| SNF Discharge Rate at DRG | 4.35 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 4.52 | ||||
| Home Discharge Rate at DRG | 81.76 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 81.16 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 834: ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 016: AUTOLOGOUS BONE MARROW TRANSPLANT WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 838: CHEMOTHERPY WITH ACUTE LEUKEMIA AS SDX WITH COMPLICATION OR COMORBIDITY (CC) OR HIGH DOSE CHEMOTHERAPY AGENT | DRG 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 12,641 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 1,213 | ||||
| DRG Share of Total Hospitalizations | 0.04 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 2.72 | ||||
| Avg LOS at DRG | 16.42 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 25.74 | ||||
| Readmission Rate at DRG | 41.54 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 50.05 | ||||
| Unplanned Readmission Rate at DRG | 17.96 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 20.51 | ||||
| Total Medicare payments at DRG | $591,889,384 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $70,028,208 | ||||
| Total Medicare payment per Day at DRG | $2,852 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $2,242 | ||||
| Total Medicare payment per Hospitalization at DRG | $46,823 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $57,731 | ||||
| Total Medicare Charges at DRG | $2,437,161,576 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $374,294,368 | ||||
| Avg Charges at DRG | $192,798 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $308,569 | ||||
| Mortality Rate at DRG | 21.77 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 19.62 | ||||
| SNF Discharge Rate at DRG | 6.6 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 7.42 | ||||
| Home Discharge Rate at DRG | 30.51 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 34.62 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 823: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER O.R. PROCEDURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 181: RESPIRATORY NEOPLASMS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 014: ALLOGENEIC BONE MARROW TRANSPLANT | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 1,808,415 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 656 | ||||
| DRG Share of Total Hospitalizations | 5.5 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 1.47 | ||||
| Avg LOS at DRG | 6.34 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 16.2 | ||||
| Readmission Rate at DRG | 24.2 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 38.72 | ||||
| Unplanned Readmission Rate at DRG | 16.78 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 27.71 | ||||
| Total Medicare payments at DRG | $21,288,214,047 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $14,541,499 | ||||
| Total Medicare payment per Day at DRG | $1,857 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $1,368 | ||||
| Total Medicare payment per Hospitalization at DRG | $11,772 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $22,167 | ||||
| Total Medicare Charges at DRG | $107,155,481,388 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $115,326,173 | ||||
| Avg Charges at DRG | $59,254 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $175,802 | ||||
| Mortality Rate at DRG | 12.11 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 14.63 | ||||
| SNF Discharge Rate at DRG | 27.18 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 18.6 | ||||
| Home Discharge Rate at DRG | 25.81 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 24.85 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 166: OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 375: DIGESTIVE MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 374: DIGESTIVE MALIGNANCY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 829: MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER O.R. PROCEDURE WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 842: LYMPHOMA AND NON-ACUTE LEUKEMIA WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 82,335 | ||||
| Total Hospitalizations with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 443 | ||||
| DRG Share of Total Hospitalizations | 0.25 | ||||
| % of Total ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach in DRG | 0.99 | ||||
| Avg LOS at DRG | 12.91 | ||||
| Avg LOS with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 16.7 | ||||
| Readmission Rate at DRG | 32.17 | ||||
| Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 36.8 | ||||
| Unplanned Readmission Rate at DRG | 19.76 | ||||
| Unplanned Readmission Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 24.0 | ||||
| Total Medicare payments at DRG | $2,324,349,241 | ||||
| Total Medicare payments with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $14,245,634 | ||||
| Total Medicare payment per Day at DRG | $2,187 | ||||
| Total Medicare payment per Day with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $1,926 | ||||
| Total Medicare payment per Hospitalization at DRG | $28,230 | ||||
| Total Medicare payment per Hospitalization with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $32,157 | ||||
| Total Medicare Charges at DRG | $11,401,334,817 | ||||
| Total Medicare Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $84,299,359 | ||||
| Avg Charges at DRG | $138,475 | ||||
| Avg Charges with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | $190,292 | ||||
| Mortality Rate at DRG | 10.6 | ||||
| Mortality Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 13.32 | ||||
| SNF Discharge Rate at DRG | 21.62 | ||||
| SNF Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 19.41 | ||||
| Home Discharge Rate at DRG | 30.12 | ||||
| Home Discharge Rate with ICD 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach | 25.96 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 1,276 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 1275 YORK AVE | NEW YORK | NY | 10065 | 1,175 |
| NEWYORK PRESBYTERIAN - WEILL CORNELL MEDICAL CENTER | 525 E 68TH ST | NEW YORK | NY | 10021 | 908 |
| MASSACHUSETTS GENERAL HOSPITAL | 55 FRUIT ST | BOSTON | MA | 02114 | |
| MAYO CLINIC HOSPITAL - SAINT MARYS CAMPUS | 1216 2ND ST SW | ROCHESTER | MN | 55902 | |
| HACKENSACK UNIVERSITY MEDICAL CENTER | 30 PROSPECT AVE | HACKENSACK | NJ | 07601 | |
| BRIGHAM AND WOMEN'S HOSPITAL | 75 FRANCIS ST | BOSTON | MA | 02115 | |
| BARNES JEWISH HOSPITAL | 1 BARNES-JEWISH HOSPITAL PLZ | SAINT LOUIS | MO | 63110 | |
| THE JOHNS HOPKINS HOSPITAL | 600 N WOLFE ST | BALTIMORE | MD | 21287 | |
| HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA | 3400 SPRUCE ST | PHILADELPHIA | PA | 19104 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 | 136 |
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 110 |
| Dr. TATYANA A FELDMAN | 92 2ND ST | HACKENSACK | NJ | 07601 | 83 |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | |
| Dr. CHRISTIAN GROMMES | 1275 YORK AVE | NEW YORK | NY | 10065 | |
| Dr. MICHAEL PATTEN CARROLL | 1020 29TH ST | SACRAMENTO | CA | 95816 | |
| Dr. SUDHA KAVURU | 40 BEY LEA RD | TOMS RIVER | NJ | 08753 | |
| Dr. HAKAN KAYA | 601 S SHERMAN ST | SPOKANE | WA | 99202 | |
| Dr. TAMARA LEA MUSGRAVE | 172 S MAYO TRL | PIKEVILLE | KY | 41501 | |
| Dr. SARAH RUTHERFORD | 520 E 70TH ST | NEW YORK | NY | 10021 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. VIKAS BHUSHAN | 7777 FOREST LN | DALLAS | TX | 75230 | 169 |
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 130 |
| Dr. TATYANA A FELDMAN | 92 2ND ST | HACKENSACK | NJ | 07601 | 92 |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | |
| Dr. MICHAEL PATTEN CARROLL | 1020 29TH ST | SACRAMENTO | CA | 95816 | |
| Dr. CHRISTIAN GROMMES | 1275 YORK AVE | NEW YORK | NY | 10065 | |
| Dr. SUDHA KAVURU | 40 BEY LEA RD | TOMS RIVER | NJ | 08753 | |
| Dr. JOHN NATHAN ALLAN | 520 E 70TH ST | NEW YORK | NY | 10021 | |
| Dr. FRANCISCO HERNANDEZ-ILIZALITURRI | ELM AND CARLTON ST | BUFFALO | NY | 14263 | |
| Dr. KAREN PATRICIA SEITER | 19 BRADHURST AVE | HAWTHORNE | NY | 10532 |